Joseph Chavarria-Smith

Joseph Chavarria-Smith

Auto-generated profile, based on publicly available information

Joseph Chavarria-Smith

Department of Immunology Discovery, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2021 in Science Immunology
Verified
Journal Article
Closed access
PDF file
CCChristian B. Cox
Christian B. Cox
ESElaine E. Storm
Elaine E. Storm
VKVarun N. Kapoor
Varun N. Kapoor
JCJoseph Chavarria-Smith
Joseph Chavarria-Smith
DLDavid L. Lin
David L. Lin
MCMenno van Lookeren Campagne
Menno van Lookeren Campagne
Repair of the intestinal epithelium is tightly regulated to maintain homeostasis. The response after epithelial damage needs to be local and proportional to the insult. How different types of damage are coupled to repair remains incompletely understood. We report that after distinct types of intestinal epithelial damage, IL-1R1 signaling in GREM1+ mesenchymal cells increases production of R-spondin 3 (RSPO3), a Wnt agonist required for intestinal stem cell self-renewal. In parallel, IL-1R1 signaling regulates IL-22 production by innate lymphoid cells and promotes epithelial hyperplasia and regeneration. Although the regulation of both RSPO3 and IL-22 is critical for epithelial recovery from Citrobacter rodentium infection, IL-1R1–dependent RSPO3 production by GREM1+ mesenchymal cells alone is sufficient and required for recovery after dextran sulfate sodium–induced colitis. These data demonstrate how IL-1R1–dependent signaling orchestrates distinct repair programs tailored to the type of injury sustained that are required to restore intestinal epithelial barrier function.

14 December 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
JCJoseph Chavarria-Smith
Joseph Chavarria-Smith
CCCecilia P.C. Chiu
Cecilia P.C. Chiu
JJJanet K. Jackman
Janet K. Jackman
JYJianping Yin
Jianping Yin
JZJuan Zhang
Juan Zhang
TYTangsheng Yi
Tangsheng Yi
The epidermis is a barrier that prevents water loss while keeping harmful substances from penetrating the host. The impermeable cornified layer of the stratum corneum is maintained by balancing continuous turnover driven by epidermal basal cell proliferation, suprabasal cell differentiation, and corneal shedding. The epidermal desquamation process is tightly regulated by balance of the activities of serine proteases of the Kallikrein-related peptidases (KLK) family and their cognate inhibitor lymphoepithelial Kazal type–related inhibitor (LEKTI), which is encoded by the serine peptidase inhibitor Kazal type 5 gene. Imbalance of proteolytic activity caused by a deficiency of LEKTI leads to excessive desquamation due to increased activities of KLK5, KLK7, and KLK14 and results in Netherton syndrome (NS), a debilitating condition with an unmet clinical need. Increased activity of KLKs may also be pathological in other dermatoses such as atopic dermatitis (AD). Here, we describe the discovery of inhibitory antibodies against murine KLK5 and KLK7 that could compensate for the deficiency of LEKTI in NS. These antibodies are protective in mouse models of NS and AD and, when combined, promote improved skin barrier integrity and reduced inflammation. To translate these findings, we engineered a humanized bispecific antibody capable of potent inhibition of human KLK5 and KLK7. A crystal structure of KLK5 bound to the inhibitory Fab revealed that the antibody binds distal to its active site and uses a relatively unappreciated allosteric inhibition mechanism. Treatment with the bispecific anti-KLK5/7 antibody represents a promising therapy for clinical development in NS and other inflammatory dermatoses.

1 March 2008 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
JCJoseph Chavarria‐Smith
Joseph Chavarria‐Smith
NRNancy A. Rice
Nancy A. Rice
Phosphorylase kinase (PhK) is a hexadecamer composed of four different subunits each encoded by a separate gene located on individual chromosomes. Muscle‐specific α and γ subunits are encoded by Phka1 and Phkg1; Phka2 and Phkg2 encode the liver variants of these subunits. The β and δ subunits are ubiquitously expressed from Phkb and calmodulin genes, respectively. To understand the transcriptional regulation of PhK, we have determined the developmental expression profile for each gene in muscle, liver and brain of both wild‐type (C57BL6) and Phka1 mutant mice (I/LnJ) by quantitative real‐time PCR and subsequently, identified novel genes by microarray analysis that may be involved in temporal and/or spatial coordination of PhK expression. Tissues were isolated at 1, 7, 14, 28 and 56 postnatal day (pnd) and Phka1, Phka2, Phkb, Phkg1 and Phkg2 transcripts were quantified. Subsequently, RNA from pnd 7, 28 and 56 from muscle and liver was analyzed on a whole mouse genome microarray. Our results indicate that: all Phk genes are developmentally regulated and increase in expression over the early postnatal period; Phka1, Phkb, and Phkg1 are expressed ~ 100‐fold higher in muscle than corresponding levels of Phka2, Phkb, and Phkg2 in liver and brain; and all Phk genes are repressed in the I/LnJ mice when compared to the same gene in the C57BL6 mice with muscle and liver expression being repressed more than brain transcription. Phka1 expression is the most variable with a 39.1‐, 7.7‐ and 4.4‐fold decrease in muscle, liver and brain respectively at pnd 56. No compensatory upregulation of Phka2 was found in any tissue. Preliminary microarray results indicate > 200 differentially expressed genes at all time points and tissues assayed between the I/LnJ and C57BL6 mice. This work was supported by the National Institute of Health grant 2PORR16481.